Episode Details
Back to Episodes
Lowering Eye Pressure: The Lumigan vs Roclanda Showdown
Description
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/lowering-eye-pressure-the-lumigan-vs-roclanda-showdown
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Lowering Eye Pressure: The Lumigan vs Roclanda Showdown Open-angle glaucoma and ocular hypertension are conditions where intraocular pressure (IOP) is higher than normal, threatening vision. Eye drops that reduce IOP are the first-line defense. In this “showdown,” we compare Lumigan (brand of bimatoprost) and Roclanda (called Rocklatan in the US, a fixed-dose combo of latanoprost + netarsudil) – explaining how each works, how well it lowers pressure, side effects, dosing, cost, and which patients might benefit most. Mechanism of Action The two drops work differently. Lumigan (bimatoprost) is a prostaglandin analogue. Prostaglandin analogues act mainly by increasing the drainage of fluid out of the eye (especially via the uveoscleral outflow pathway). Bimatoprost is converted in the eye to a form that boosts outflow of aqueous humor, reducing pressure. For example, laboratory studies show bimatoprost lowers resistance in the trabecular meshwork by about 26% (). Clinically, bimatoprost and other prostaglandins (like latanoprost) share this main effect: more fluid drain leads to lower IOP () (). Roclanda (latanoprost + netarsudil) combines two actions. The latanoprost part is another prostaglandin, working like bimatoprost to improve outflow. On top of that, netarsudil is a Rho kinase (ROCK) inhibitor – a different class. Netarsudil’s unique action is to relax the eye’s conventional drainage meshwork (trabecular meshwork) and lower the pressure needed to push fluid out. It also has secondary effects: it can reduce pressure in the episcleral veins and even slightly reduce fluid production (). In short, while both drugs share the prostaglandin mechanism (increasing uveoscleral drainage ()), netarsudil adds a tug at the trabecular outflow route and venous side of things (). Efficacy Clinical trials show both Lumigan and the netarsudil/latanoprost combo can dramatically lower IOP, but the combo generally drops pressure further than latanoprost alone (and thus more than a single prostaglandin alone). Lumigan monotherapy typically reduces IOP by a large percentage. In trials of bimatoprost 0.03%, average drops of about 6–8 mmHg (roughly 25–35%) from baseline were seen (). For example, one analysis noted an average reduction around 7.7 mmHg. This means from a starting IOP in the mid-20s, many patients on Lumigan drop into the high teens. In fact, bimatoprost has consistently shown strong pressure-lowering: multiple studies and meta-analyses found it often lowers IOP slightly more than other prostaglandins like latanoprost (). For Roclanda/Rocklatan (netarsudil+latanoprost), phase-3 trials (the MERCURY studies) found even bigger drops compared to each drug alone. In those trials, adding netarsudil to latanoprost produced an extra 1.5–3 mmHg reduction in IOP beyond latanoprost alone (). In concrete terms, patients on the combination averaged IOPs around 15–16 mmHg at follow-up, compared to about 17–18 mmHg on latanoprost alone () (). Notably, at 3 months one study reported 42% of patients on the combo hit a mean pressure ≤15 mmHg, while only about 16–18% did so on latanoprost or netarsudil alone (). In pooled analyses, Roclanda patients had mean daytime IOP ~15–16 mmHg versus ~17–18 mmHg on latanoprost alone (). There are no direct head-to-head trials comparing Lumigan vs the netarsudil/latanoprost combo. (The recent MERCURY-3